ANHYDROUS LACTOSE

Molecular Excipient

Mwt. LogP HBD HBA PSA RB CSP3
342.0 -5.6 8 11 197.0 8 0.92
CAS
63423
UNII
3SY5LH9PMK
SYNONYMS
ZINC ID(s)
Availability
Present in 5 ZINC catalogs

Known Active Genes

There has not been any activity reported at 10μM or less for this excipient (per ChEBML)

Clinical Trials

This compound has not been in (or located in) any clinical trials (per clinicaltrials.gov).

(Browse) Purchasable Analogs in ZINC

Dosages

Route Formulation Per Unit Dose
Buccal Tablet 23.75MG
Im - Iv Injectable 2.5%
Im - Iv Powder, For Injection Solution 2.5%
Intracavitary Powder, For Injection Solution, Lyophilized 4.75%
Intravenous Powder, For Injection Solution, Lyophilized 28.75%
Iv(infusion) Powder, For Injection Solution 2.5%
Oral Capsule (immed./comp. Release) 46.06MG
Oral Capsule, Coated, Soft Gelatin 71.91MG
Oral Capsule, Delayed Release 40MG
Oral Capsule, Enteric Coated Pellets 117MG
Oral Capsule, Hard Gelatin 238.24MG
Oral Capsule, Sustained Action 300.8MG
Oral Granule 433MG
Oral Granule, For Reconstitution 15.69MG
Oral Powder, For Inhalation 0.12%
Oral Tablet 735.2MG
Oral Tablet (immed./comp. Release), Coated 93.3MG
Oral Tablet (immed./comp. Release), Film Coated 126.3MG
Oral Tablet (immed./comp. Release), Uncoated, Buccal 98.7MG
Oral Tablet (immed./comp. Release), Uncoated, Chewable 108MG
Oral Tablet, Coated 144.19MG
Oral Tablet, Delayed Action 333MG
Oral Tablet, Delayed Action, Enteric Coated 90MG
Oral Tablet, Delayed Release 145MG
Oral Tablet, Extended Release 177.25MG
Oral Tablet, Film Coated 453.6MG
Oral Tablet, Film Coated, Extended Release 48MG
Oral Tablet, Sustained Action 180.9MG
Oral Tablet, Sustained Action, Coated 130.7MG
Oral Tablet, Sustained Action, Film Coated 157.95MG
Oral-21 Tablet 75.69MG
Oral-21 Tablet, Coated 58MG
Oral-28 Tablet 79.34MG
Oral-28 Tablet, Coated 58MG
Sublingual Tablet 128MG
Vaginal Tablet 605MG

More Information

Usage Over Time

Comments